DCEP-T:An Effective,Tolerated,Salvage Combination Chemotherapy for Relapsed or Refractory Multiple Myeloma

Objective 　To investigate the efficacy of DCEP2T regimen in t reatment of patient s with re2 lapsed or ref ractory multiple myeloma (MM) . Methods 　Twenty2eight patient s (19 male and 9 female, median age is 49 years) with ref ractory or relapsed myeloma had been t reated with DCEP2T for at least two cycles. The regimen consisted of 4 days of int ravenous dexamethasone (20～40) mg/ d, cyclophospha2 mide 200 mg/ d, etoposide 40 mg/ m2, cisplatin 10 mg/ m2, and daily thalidomide (100～200) mg/ d in a 42 week cycle. Results 　After two cycles of DCEP2T, 4 patient s (14. 3 %) achieved very good complete re2 sponse, and 14 patient s (50. 0 %) had a partial response. So the overall response rate was 64. 3 %. Among the 9 patient s with ext ramedullary evolvement, plasmacytoma completely disappeared in 4 patient s, and decreased markedly in 2 patient s, the response rate was 66. 7 %(6/ 9) . The most common nonhematologic toxicities were nausea and vomiting (32. 1 %), followed by constipation (25. 0 %) . Conclusion 　DCEP2T is an effective, tolerable, salvage combination chemotherapy for relapsed or ref ractory MM, as well as in ext ramedullary evolvement .